🚨 Pfizer Seeks FDA Approval for RSV Vaccine for Young Adults, Is Also Conducting RSV Trial for Kids as Young as 2
Four members of the FDA’s vaccine advisory committee voted against approving the drug because they said the safety data weren’t adequate given concerns regarding Guillain-Barré.
Despite their concerns, the FDA approved the drug.
⬇️
https://childrenshealthdefense.org/defender/pfizer-fda-approval-rsv-vaccine-young-adults-trial-kids/?utm_source=sovren&utm_medium=social&utm_campaign=defender&utm_id=20240409
Pfizer said Tuesday it plans to use data from a clinical trial it concluded last month to seek expanded approval of its RSV vaccine, Abrysvo, for all adults ages 18 and up. The vaccine maker also said it has begun trials for the drug in children ages 2-18.
childrenshealthdefense.org
0
Share on Telegram
Share on Facebook
Share on Twitter
Share on Reddit